540 related articles for article (PubMed ID: 20207347)
1. Effects of the alpha4beta2 partial agonist varenicline on brain activity and working memory in abstinent smokers.
Loughead J; Ray R; Wileyto EP; Ruparel K; Sanborn P; Siegel S; Gur RC; Lerman C
Biol Psychiatry; 2010 Apr; 67(8):715-21. PubMed ID: 20207347
[TBL] [Abstract][Full Text] [Related]
2. Brain activity and emotional processing in smokers treated with varenicline.
Loughead J; Ray R; Wileyto EP; Ruparel K; O'Donnell GP; Senecal N; Siegel S; Gur RC; Lerman C
Addict Biol; 2013 Jul; 18(4):732-8. PubMed ID: 21507156
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of a nicotine (4 mg)-containing lozenge on the cognitive impairment of nicotine withdrawal.
Atzori G; Lemmonds CA; Kotler ML; Durcan MJ; Boyle J
J Clin Psychopharmacol; 2008 Dec; 28(6):667-74. PubMed ID: 19011436
[TBL] [Abstract][Full Text] [Related]
4. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.
Nides M; Oncken C; Gonzales D; Rennard S; Watsky EJ; Anziano R; Reeves KR
Arch Intern Med; 2006 Aug 14-28; 166(15):1561-8. PubMed ID: 16908788
[TBL] [Abstract][Full Text] [Related]
5. Varenicline: a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist approved for smoking cessation.
Lam S; Patel PN
Cardiol Rev; 2007; 15(3):154-61. PubMed ID: 17438382
[TBL] [Abstract][Full Text] [Related]
6. Varenicline for smoking cessation: a placebo-controlled, randomized study.
Wang C; Xiao D; Chan KP; Pothirat C; Garza D; Davies S
Respirology; 2009 Apr; 14(3):384-92. PubMed ID: 19192221
[TBL] [Abstract][Full Text] [Related]
7. Varenicline improves mood and cognition during smoking abstinence.
Patterson F; Jepson C; Strasser AA; Loughead J; Perkins KA; Gur RC; Frey JM; Siegel S; Lerman C
Biol Psychiatry; 2009 Jan; 65(2):144-9. PubMed ID: 18842256
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.
Rollema H; Chambers LK; Coe JW; Glowa J; Hurst RS; Lebel LA; Lu Y; Mansbach RS; Mather RJ; Rovetti CC; Sands SB; Schaeffer E; Schulz DW; Tingley FD; Williams KE
Neuropharmacology; 2007 Mar; 52(3):985-94. PubMed ID: 17157884
[TBL] [Abstract][Full Text] [Related]
9. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.
Coe JW; Brooks PR; Vetelino MG; Wirtz MC; Arnold EP; Huang J; Sands SB; Davis TI; Lebel LA; Fox CB; Shrikhande A; Heym JH; Schaeffer E; Rollema H; Lu Y; Mansbach RS; Chambers LK; Rovetti CC; Schulz DW; Tingley FD; O'Neill BT
J Med Chem; 2005 May; 48(10):3474-7. PubMed ID: 15887955
[TBL] [Abstract][Full Text] [Related]
10. Nicotine effects on brain function and functional connectivity in schizophrenia.
Jacobsen LK; D'Souza DC; Mencl WE; Pugh KR; Skudlarski P; Krystal JH
Biol Psychiatry; 2004 Apr; 55(8):850-8. PubMed ID: 15050867
[TBL] [Abstract][Full Text] [Related]
11. Single- and multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy Japanese adult smokers.
Kikkawa H; Maruyama N; Fujimoto Y; Hasunuma T
J Clin Pharmacol; 2011 Apr; 51(4):527-37. PubMed ID: 20551220
[TBL] [Abstract][Full Text] [Related]
12. A functional MRI study of the effects of bromocriptine, a dopamine receptor agonist, on component processes of working memory.
Gibbs SE; D'Esposito M
Psychopharmacology (Berl); 2005 Aug; 180(4):644-53. PubMed ID: 16001111
[TBL] [Abstract][Full Text] [Related]
13. A comparison of brain and behavioral effects of varenicline and nicotine in rats.
King J; Huang W; Chen W; Heffernan M; Shields J; Rane P; Bircher R; DiFranza JR
Behav Brain Res; 2011 Sep; 223(1):42-7. PubMed ID: 21527291
[TBL] [Abstract][Full Text] [Related]
14. Single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers.
Faessel HM; Smith BJ; Gibbs MA; Gobey JS; Clark DJ; Burstein AH
J Clin Pharmacol; 2006 Sep; 46(9):991-8. PubMed ID: 16920893
[TBL] [Abstract][Full Text] [Related]
15. Neural Signatures of Cognitive Flexibility and Reward Sensitivity Following Nicotinic Receptor Stimulation in Dependent Smokers: A Randomized Trial.
Lesage E; Aronson SE; Sutherland MT; Ross TJ; Salmeron BJ; Stein EA
JAMA Psychiatry; 2017 Jun; 74(6):632-640. PubMed ID: 28403383
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation.
Oncken C; Gonzales D; Nides M; Rennard S; Watsky E; Billing CB; Anziano R; Reeves K
Arch Intern Med; 2006 Aug 14-28; 166(15):1571-7. PubMed ID: 16908789
[TBL] [Abstract][Full Text] [Related]
17. Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers.
Faessel HM; Gibbs MA; Clark DJ; Rohrbacher K; Stolar M; Burstein AH
J Clin Pharmacol; 2006 Dec; 46(12):1439-48. PubMed ID: 17101743
[TBL] [Abstract][Full Text] [Related]
18. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors.
Mihalak KB; Carroll FI; Luetje CW
Mol Pharmacol; 2006 Sep; 70(3):801-5. PubMed ID: 16766716
[TBL] [Abstract][Full Text] [Related]
19. Nicotine replacement in abstinent smokers improves cognitive withdrawal symptoms with modulation of resting brain network dynamics.
Cole DM; Beckmann CF; Long CJ; Matthews PM; Durcan MJ; Beaver JD
Neuroimage; 2010 Aug; 52(2):590-9. PubMed ID: 20441798
[TBL] [Abstract][Full Text] [Related]
20. Effect of nicotine lozenges on affective smoking withdrawal symptoms: secondary analysis of a randomized, double-blind, placebo-controlled clinical trial.
Shiffman S
Clin Ther; 2008 Aug; 30(8):1461-75. PubMed ID: 18803988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
